Europeiska unionen - estniska - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Europeiska unionen - estniska - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - rinnanäärmed - endokriinset ravi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Europeiska unionen - estniska - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukeemia, müeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.

Europeiska unionen - estniska - EMA (European Medicines Agency)

united therapeutics europe ltd - dinutuximab - neuroblastoom - antineoplastilised ained - unituxin on näidustatud suure riskiga neuroblastoma patsienti vanuses 12 kuud kuni 17-aastased, kes on varem saanud induktsioon keemiaravi ja saavutatud vähemalt osaline ravivastus, kes saavad müeloablatiivset ravi ja vereloome tüvirakkude siirdamist (asct). seda manustatakse kombinatsioonis granulotsüütide ja makrofaagide kolooniat stimuleeriva faktoriga (gm-csf), interleukiin-2 (il-2) ja isotretinoiiniga.

Europeiska unionen - estniska - EMA (European Medicines Agency)

zentiva, k.s. - pregabaliin - anxiety disorders; epilepsy - antiepileptics, - neuropathic pain , pregabalin zentiva is indicated for the treatment of peripheral and central neuropathic pain in adults. , epilepsy , pregabalin zentiva is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. , generalised anxiety disorder , pregabalin zentiva is indicated for the treatment of generalised anxiety disorder (gad) in adults.

Estland - estniska - Ravimiamet

fresenius kabi ab - elektrolüüdid - infusioonilahuse kontsentraat - 10ml 20tk

Europeiska unionen - estniska - EMA (European Medicines Agency)

elanco gmbh - spinosaad - muud nahaparasiidi-süsteemseks kasutamiseks - dogs; cats - kirpude nakatumise ravi ja ennetamine (ctenocephalides felis). ennetav mõju vastu uuesti levikust, on tulemus adulticidal tegevust ja vähendada munade tootmiseks ning, mis püsib kuni 4 nädalat pärast ühekordset manustamist toode. veterinaarravimit saab kasutada kirbari allergia dermatiidi (fad) ravistrateegia osana..

Europeiska unionen - estniska - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastilised ained - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Europeiska unionen - estniska - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Europeiska unionen - estniska - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastilised ained - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.